Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AMPE NASDAQ:NIVF NYSE:NVTA NASDAQ:PTPI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPEAmpio Pharmaceuticals$0.18$0.16$0.00▼$0.64$208K5.962,326 shsN/ANIVFNewGenIvf Group$0.93-9.3%$1.66$0.72▼$1,839.00$225K0.041.44 million shs406,500 shsNVTAInvitae$0.00$0.00$0.02▼$0.02$80K1.5923.72 million shsN/APTPIPetros Pharmaceuticals$0.01$0.01$0.00▼$0.04$190K1.91106,685 shs31,297 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPEAmpio Pharmaceuticals0.00%0.00%+3,421.15%-36.86%+6,003.33%NIVFNewGenIvf Group+21.16%-8.04%-45.79%-68.98%-99.85%NVTAInvitae0.00%0.00%0.00%0.00%0.00%PTPIPetros Pharmaceuticals0.00%-4.69%-15.28%-12.86%-83.91%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPEAmpio Pharmaceuticals$0.18$0.16$0.00▼$0.64$208K5.962,326 shsN/ANIVFNewGenIvf Group$0.93-9.3%$1.66$0.72▼$1,839.00$225K0.041.44 million shs406,500 shsNVTAInvitae$0.00$0.00$0.02▼$0.02$80K1.5923.72 million shsN/APTPIPetros Pharmaceuticals$0.01$0.01$0.00▼$0.04$190K1.91106,685 shs31,297 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPEAmpio Pharmaceuticals0.00%0.00%+3,421.15%-36.86%+6,003.33%NIVFNewGenIvf Group+21.16%-8.04%-45.79%-68.98%-99.85%NVTAInvitae0.00%0.00%0.00%0.00%0.00%PTPIPetros Pharmaceuticals0.00%-4.69%-15.28%-12.86%-83.91%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPEAmpio Pharmaceuticals 0.00N/AN/AN/ANIVFNewGenIvf Group 1.00SellN/AN/ANVTAInvitae 0.00N/AN/AN/APTPIPetros Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NVTA, NIVF, AMPE, and PTPI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/27/2026NIVFNewGenIvf Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPEAmpio PharmaceuticalsN/AN/AN/AN/A$4.04 per shareN/ANIVFNewGenIvf Group$4.73M0.05$46.70 per share0.02$105.78 per share0.01NVTAInvitae$481.58M0.00N/AN/A$0.42 per share0.00PTPIPetros Pharmaceuticals$5.11M0.04N/AN/A$4.04 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPEAmpio Pharmaceuticals-$8.63M-$11.01N/AN/AN/AN/AN/AN/AN/ANIVFNewGenIvf Group$9.88MN/AN/A0.10N/AN/AN/AN/A6/30/2026 (Estimated)NVTAInvitae-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/APTPIPetros Pharmaceuticals-$8.16M-$1.64N/AN/AN/AN/A-78.22%-23.50%N/ALatest NVTA, NIVF, AMPE, and PTPI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/31/2026Q4 2025NIVFNewGenIvf GroupN/A-$287.24N/A-$287.24N/A$1.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/ANIVFNewGenIvf GroupN/AN/AN/AN/AN/ANVTAInvitaeN/AN/AN/AN/AN/APTPIPetros PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPEAmpio PharmaceuticalsN/AN/AN/ANIVFNewGenIvf Group0.163.122.98NVTAInvitaeN/A2.392.25PTPIPetros Pharmaceuticals1.580.850.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPEAmpio Pharmaceuticals5.73%NIVFNewGenIvf Group66.24%NVTAInvitae61.28%PTPIPetros Pharmaceuticals12.34%Insider OwnershipCompanyInsider OwnershipAMPEAmpio Pharmaceuticals3.30%NIVFNewGenIvf Group31.80%NVTAInvitae0.74%PTPIPetros Pharmaceuticals8.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPEAmpio Pharmaceuticals201.14 million1.10 millionNo DataNIVFNewGenIvf GroupN/A250,000168,000N/ANVTAInvitae1,700267.01 million284.37 millionNo DataPTPIPetros Pharmaceuticals2031.16 million9.93 millionNot OptionableNVTA, NIVF, AMPE, and PTPI HeadlinesRecent News About These CompaniesPetros Pharmaceuticals Delays Annual 10-K FilingMarch 31, 2026 | tipranks.comPetros Pharmaceuticals grants significant RSUs to key leadersJanuary 3, 2026 | msn.comPetros Pharmaceuticals to be Delisted from NasdaqNovember 7, 2025 | msn.comPetros Pharmaceuticals Inc (PTPI) - Investing.comSeptember 6, 2025 | investing.comPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company ...June 26, 2025 | finanznachrichten.dePetros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position | MorningstarJune 26, 2025 | morningstar.comMPetros Pharmaceuticals to deconsolidate subsidiary to improve financesJune 26, 2025 | investing.comPetros Pharmaceuticals, Inc. (PTPI) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comPetros Pharmaceuticals Inc News (PTPI) - Investing.comJune 26, 2025 | investing.comPetros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity PositionJune 25, 2025 | accessnewswire.comAPetros Pharmaceuticals to appeal Nasdaq delisting decisionMay 23, 2025 | uk.investing.comPetros Pharmaceuticals Announces Transition from NASDAQ to OTC MarketsMay 21, 2025 | accessnewswire.comAPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device DeveloperMay 20, 2025 | finanznachrichten.dePetros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device DeveloperMay 20, 2025 | accessnewswire.comAPetros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI PlatformMay 6, 2025 | accessnewswire.comAPetros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification ReformsApril 29, 2025 | accessnewswire.comAPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple IndicationsMarch 20, 2025 | finanznachrichten.dePetros Pharmaceuticals enters collaboration with big data, analytics firmMarch 20, 2025 | msn.comPetros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple IndicationsMarch 20, 2025 | accessnewswire.comAPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal StudyFebruary 27, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVTA, NIVF, AMPE, and PTPI Company DescriptionsAmpio Pharmaceuticals NYSE:AMPE$0.18 0.00 (0.00%) As of 05/28/2026Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.NewGenIvf Group NASDAQ:NIVF$0.93 -0.10 (-9.32%) As of 03:20 PM Eastern This is a fair market value price provided by Massive. Learn more.NewGenIVF Group Ltd. operates as an assisted reproductive services provider. It focuses on providing fertility treatments to fulfil the dreams of building families. The firm offers in-vitro fertilization treatment service, comprising traditional IVF and egg donation, and surrogacy and ancillary caring services. The company was founded by Siu Wing Fung and Fong Hei Yue on January 16, 2019 and is headquartered in Bangkok, Thailand.Invitae NYSE:NVTAInvitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.Petros Pharmaceuticals NASDAQ:PTPI$0.0061 0.00 (0.00%) As of 12:24 PM EasternPetros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
